<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043588</url>
  </required_header>
  <id_info>
    <org_study_id>K060401</org_study_id>
    <nct_id>NCT01043588</nct_id>
  </id_info>
  <brief_title>TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management</brief_title>
  <acronym>REVAPRO</acronym>
  <official_title>Transurethral Resection of the Prostate With Photo Selective Vaporization of the Prostate Using the High Powered 532nm Laser Obstructive Benign Prostatic Hyperplasia Management: Focus on Efficiency and Cost-effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare medical efficacy and cost effectiveness of two surgical&#xD;
      options for obstructive BPH management : transurethral resection of the prostate with photo&#xD;
      selective vaporization of the prostate using the high powered 532nm laser.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare medical efficacy and cost effectiveness of two surgical&#xD;
      options for obstructive BPH management : transurethral resection of the prostate with photo&#xD;
      selective vaporization of the prostate using the high powered 532nm laser. Patients were&#xD;
      randomized in two groups after inclusion. Perioperative data were collected, and follow-up&#xD;
      was conducted for one month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>end of hospitalization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical symptoms at 1-yr follow-up evaluated with usual objective and subjective parameters</measure>
    <time_frame>at one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complication needing re-hospitalisation or reintervention</measure>
    <time_frame>from the surgical procedure until one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of ignoring a localized prostate cancer needing a curative management.</measure>
    <time_frame>at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and post-operative costs during follow-up.</measure>
    <time_frame>from the surgical procedure until one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of side effects during follow-up.</measure>
    <time_frame>from the surgical procedure until one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>during follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>during follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>1 : TURP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery: TransUrethral Resection of the Prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 : PVP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery: Photo selective Vaporization of the Prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TURP</intervention_name>
    <description>TransUrethral Resection of the Prostate</description>
    <arm_group_label>1 : TURP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVP</intervention_name>
    <description>Photo selective Vaporization of the Prostate</description>
    <arm_group_label>2 : PVP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, 50 years of age or older.&#xD;
&#xD;
          2. American Society of Anesthesiology (ASA) classification of physical status, class 1-3&#xD;
&#xD;
          3. Signed an informed consent at the beginning of the study.&#xD;
&#xD;
          4. Patients presenting with LUTS associated to benign prostatic enlargement for more than&#xD;
             3 months, needing a surgical management, with at least one of the following&#xD;
             situations: disability score ≥3, I-PSS ≥12, or full urinary retention&#xD;
&#xD;
          5. Qmax ≤12ml /s for no drained patients with voided volume&gt; 125 ml.&#xD;
&#xD;
          6. Estimated prostate weight between 25g and 80g&#xD;
&#xD;
          7. Patient free of catheter with PVR ≤ 300cc&#xD;
&#xD;
          8. Patient without renal disorders.&#xD;
&#xD;
          9. No prostate cancer suspicion at clinical examination, including DRE.&#xD;
&#xD;
         10. PSA ≤ 10 ng/ml, with negative prostate biopsies of PSA is between 4 and 10 ng/mL if&#xD;
             patient is 75 years or younger or has a life expectancy of more than 10 years.&#xD;
&#xD;
         11. In case of anticoagulation or anti-aggregation therapy, necessary preoperative visit&#xD;
             by anaesthesiologist to determine the supply therapy around surgery.&#xD;
&#xD;
         12. In case of current BPH medical management, alpha blockers and herbal medicines should&#xD;
             be stopped one week before surgery and 5-alpha-reductase-inhibitors should be stopped&#xD;
             one month before surgery.&#xD;
&#xD;
         13. Patient must be affiliated to the French social healthcare or equivalent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled cardiopulmonary disorder, previously or recently diagnosed by standard&#xD;
             methods&#xD;
&#xD;
          2. Assessed sphincter detrusor dyssynergia, or myasthenia, multiple sclerosis, or&#xD;
             Parkinson disease.&#xD;
&#xD;
          3. History of pelvic lesions with abdominal sphincter injury.&#xD;
&#xD;
          4. Urinary tract infection without antibiotics.&#xD;
&#xD;
          5. Patient with urinary catheter or suprapubic catheter because of an acute urinary&#xD;
             retention linked to an alternative diagnosis or impaired bladder sensation.&#xD;
&#xD;
          6. Subject with neurogenic bladder and/or sphincter abnormalities&#xD;
&#xD;
          7. Subject with confirmed or suspected malignancy of the prostate or the bladder.&#xD;
&#xD;
          8. Previous prostatic surgery.&#xD;
&#xD;
          9. History of bladder stone, major hematuria, urethral stricture, bladder neck stenosis.&#xD;
&#xD;
         10. Patient having a prosthesis in the procedure area&#xD;
&#xD;
         11. Patient with an active anorectal disease&#xD;
&#xD;
         12. Treatment emergency&#xD;
&#xD;
         13. Individual unable to respect timing and visits determined by the protocol.&#xD;
&#xD;
         14. Constitutional hemostasis and coagulation abnormalities not linked to oral medications&#xD;
&#xD;
         15. Any disease or patient condition which can be a contra indication to his enrolment in&#xD;
             the study, according to the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand LUKACS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital TENON - Service d'Urologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert HH, Müller A, Lehmann K, Sulser T. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005 Dec;48(6):965-71; discussion 972. Epub 2005 Jul 18.</citation>
    <PMID>16126327</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Prostate</keyword>
  <keyword>Laser 532 nm</keyword>
  <keyword>Photo selective Vaporization of the Prostate (PVP)</keyword>
  <keyword>TransUrethral Resection of the Prostate (TURP)</keyword>
  <keyword>Men health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

